2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

ASH 2025 Review: Updates in Frontline & R/R DLBCL

University of Colorado Division of Hematology

M. Kamdar

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

ASH 2024 Insights: Timing of CAR-T Failure as a Predictor of Outcome…

2024 ASH Annual Meeting Insights Hub

E. Shumilov

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch

2025 Updates in DLBCL

Total Health

F. Hagemeister

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi